Koers Onconova Therapeutics Inc Nasdaq
Aandelen
US68232V1089
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 210K 193K | Omzet 2025 * | 300K 276K | Marktkapitalisatie | 13,71 mln. 12,61 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,16 mln. | Nettowinst (verlies) 2025 * | -28 mln. -25,76 mln. | EV/omzet 2024 * | 65,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 45,7 x |
K/w-verhouding 2024 * |
-0,75
x | K/w-verhouding 2025 * |
-0,78
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,39% |
Recentste transcriptie over Onconova Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19-01-15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01-09-13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01-07-15 |
Jack Stover
BRD | Director/Board Member | 69 | 23-05-16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01-04-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+28,61% | 49,18 mld. | |
+0,83% | 42,11 mld. | |
+50,47% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+13,74% | 26,09 mld. | |
-22,18% | 18,71 mld. | |
+7,93% | 13,26 mld. | |
+32,44% | 12,32 mld. | |
-0,56% | 11,99 mld. |